The diagnosis can be confirmed with genetic testing. Diagnosis of the disease is based on testing the levels of a molecule called very long-chain fatty acids (VLCFA). X-ALD is caused by a variation (mutation) in the ABCD1 gene and it is inherited in an X-linked. There are three forms of X-ALD: a childhood cerebral form, an adrenomyeloneuropathy (AMN) type, and an adrenal-insufficiency-only-type. This is called adrenocortical insufficiency, or Addison disease. They may also have a shortage of certain hormones that is caused by damage to the outer layer of the adrenal glands (adrenal cortex). People with this disease often have progressive loss of the fatty covering (myelin) that surrounds the nerves in the brain and spinal cord. X linked adrenoleukodystrophy (X-ALD) is a genetic disease that affects the nervous system and the adrenal glands (small glands located on top of each kidney). It further highlights the inactive pipeline products in this space. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The “X linked Adrenoleukodystrophy - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X linked Adrenoleukodystrophy pipeline landscape.
0 kommentar(er)
